Industry sustainability case studies
The examples in this study provide a snapshot of the activities happening around the world to cut carbon emissions, save water, cut waste, sustainably design products.
Read more
In December 2020, we witnessed a scientific feat that will go down in history books. This was just 10 months after the WHO declared COVID-19 a pandemic.
Read moreFor World Diabetes Day on 14 November, Ann-Lise Mikolajczak, Associate Manager, Value and Access and James Anderson, Executive Director of Global Health, sat down to discuss global diabetes care. This Q&A was developed in collaboration with HYPER Network, a platform for young industry professionals.
Read moreThe discovery of insulin in 1921 changed type 1 diabetes from a death sentence to a condition that can be controlled and managed successfully. Yet a hundred years later, children still die from diabetes, especially in low- and middle-income countries (LMICs).
Read moreNovember 5, 2021 –We, as founding members of AMATA, representing patients, academia, civil society, and industry, welcome the official ratification of the AMA Treaty, which has enabled the African Medicines Agency to effectively enter into force today. We now call on the African Union to build on the current momentum gained with the legal deposition...
Read moreGlobal public health is inextricably linked to the health of the planet. Climate change, air pollution and other environmental challenges have a demonstrable impact on public health around the world.
Read moreThe examples in this study provide a snapshot of the activities happening around the world to cut carbon emissions, save water, cut waste, sustainably design products.
Read more
On 7 July 2021, the biopharmaceutical industry welcomed the opportunity to join the International Coalition of Medicines Regulatory Authorities (ICMRA) in a workshop focused on expanding manufacturing capacity for COVID-19 medicines and vaccines. This workshop provided a platform to collectively explore the range of activities associated with post-approval site transfers and review the regulatory flexibilities...
Read moreThe annual World Health Summit (WHS) provided a platform for the global health community to take stock of the world’s response to the current COVID-19 pandemic, as well other pressing health threats, such as the rise of antimicrobial resistance, which could next sweep the world. At the WHS, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced its policy perspectives on preparing society against future pandemics.
Read moreThis month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity. At current production rates, swiftly rolling out vaccines to those who still need them looks achievable, if the political...
Read moreThe session featured government and private sector leaders to officially launch the modernized APEC Kuala Lumpur and Mexico City Principles to commence the implementation process. This session also debuted a novel piece of research to serve all stakeholders in the initiative to create a better understanding of the impact of ethical business practices, especially amidst COVID-19.
Read more
This position paper details two ambitious objectives of the pharmaceutical industry: Aim to develop effective and safe pandemic products within 100 days of a new pandemic declaration. To Collaborate with governments, multilateral organizations, regulators, and other companies and sectors to ensure equitable access to those products for people worldwide.
Read more
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) - IFPMA CPP Network Training Toolkit
Read more